A Phase 1 Study of CPTX2309 in Healthy Adults and Adults with Rheumatoid Arthritis or Lupus

Study Description

A first-in-human study testing a new intravenous medication called CPTX2309 to evaluate its safety in healthy volunteers and in people living with moderate to severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

Study Details

Registry ID:

NCT06917742

Conditions:

Healthy Volunteers, Rheumatoid Arthritis, Systemic Lupus Erythematosus

Phase:

Phase 1

Target Enrollment:

64 participants

Start Date:

April 9, 2025

Age Range:

18–65 years

Healthy Volunteers:

No

Study Locations (2 sites)

• Linear Clinical Research
  Nedlands, Western AustraliaAustralia, Australia
• Veritus Research
  Bayswater, VictoriaAustralia, Australia

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.org.

View full study details and check eligibility →